Results 221 to 230 of about 26,674 (238)

Abatacept

Reactions Weekly, 2022
openaire   +1 more source

Efficacy and safety of abatacept in interstitial lung disease of rheumatoid arthritis: A systematic literature review.

Autoimmunity Reviews, 2021
E. Vicente-Rabaneda, B. Atienza-Mateo, R. Blanco, L. Cavagna, J. Ancochea, S. Castañeda, M. González-Gay   +6 more
semanticscholar   +1 more source

Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial

Lancet, The, 2011
Tihamer Orban, Linda A Dimeglio, Stephen E Gitelman   +2 more
exaly  

Efficacy and Safety of Abatacept in Lupus Nephritis: A Twelve‐Month, Randomized, Double‐Blind Study

Arthritis and Rheumatology, 2014
Kathleen Nicholls, Ruben Burgos-Vargas
exaly  

Abatacept

Reactions Weekly, 2013
openaire   +2 more sources

The efficacy and safety of abatacept in patients with non–life‐threatening manifestations of systemic lupus erythematosus: Results of a twelve‐month, multicenter, exploratory, phase IIb, randomized, double‐blind, placebo‐controlled trial

Arthritis and Rheumatism, 2010
Peter Nash
exaly  

Head‐to‐head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: Findings of a phase IIIb, multinational, prospective, randomized study

Arthritis and Rheumatism, 2013
Michael E Weinblatt, Désirée M Van Der Heijde, Roy M Fleischmann   +2 more
exaly  

Attenuation of Follicular Helper T Cell–Dependent B Cell Hyperactivity by Abatacept Treatment in Primary Sjögren's Syndrome

Arthritis and Rheumatology, 2017
Gwenny M Verstappen, Odilia B J Corneth, Suzanne Arends   +2 more
exaly  

Abatacept in the treatment of patients with psoriatic arthritis: Results of a six‐month, multicenter, randomized, double‐blind, placebo‐controlled, phase II trial

Arthritis and Rheumatism, 2011
Philip J Mease, Mark C Genovese, Christopher T Ritchlin   +2 more
exaly  

A Randomized, Double‐Blind Trial of Abatacept (CTLA‐4Ig) for the Treatment of Takayasu Arteritis

Arthritis and Rheumatology, 2017
David Cuthbertson, Nader Khalidi, Paul A Monach   +2 more
exaly